Healx vs SigTuple

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Healx employs 1-50 people, while SigTuple has 100-500 employees.

Healx has raised more in total funding at $47M, compared to SigTuple's $20M — a gap of $27M.

SigTuple holds the higher Awaira Score at 60/100, compared to Healx's 55/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 5-point gap that reflects meaningful differences in scale or traction.

Healx was founded by Tim Guilliams in 2014. SigTuple was founded by Rohit Kumar Pandey in 2015. Visit each company's profile on Awaira for a full founder biography.

Healx: Healx uses AI to identify and develop treatments for rare diseases, applying graph neural networks and multi-omics data analysis to repurpose existing approved drugs for new orphan disease indications. The Cambridge-based company focuses exclusively on rare diseases, where the small patient populations and limited existing literature make traditional drug discovery economically unviable without computational approaches that can extract signal from sparse data.\n\nThe company raised a $47 million Series B led by Balderton Capital and includes strategic investors from the rare disease patient advocacy community. Healx has assembled a pipeline of repurposing candidates for conditions including Fragile X syndrome, tuberous sclerosis complex, and other rare neurodevelopmental disorders, with several candidates advancing into clinical studies. The company partners with patient advocacy groups to access natural history data and patient registries that inform its disease models.\n\nHealx operates in a rare disease AI market that is less crowded than oncology-focused drug discovery AI but equally challenging due to regulatory complexity and small trial populations. The company competes with Healios, BenevolentAI, and specialist rare disease biotechs that are increasingly adopting computational methods. Its exclusive focus on rare diseases and its community partnerships represent a defensible niche that larger generalist AI drug discovery platforms have not prioritised. SigTuple: SigTuple develops AI-powered automated pathology solutions that digitize and analyze microscopy slides for blood, urine, sputum, and semen samples, enabling high-throughput diagnostic testing without the constant presence of trained pathologists. The company's AI-Minth platform uses robotic sample preparation, high-resolution imaging, and deep learning analysis to deliver diagnostic-grade results.\n\nThe company raised approximately $20M in Series B funding and has deployed its automated microscopy systems at diagnostic labs, hospitals, and blood banks across India, processing millions of diagnostic samples. SigTuple has received regulatory approvals for its diagnostic AI products and has established partnerships with major diagnostic laboratory chains.\n\nIndia faces a severe shortage of qualified pathologists relative to population, creating an acute need for AI-assisted diagnostic automation. SigTuple's approach of combining hardware, robotics, and AI in an integrated system addresses the complete diagnostic workflow rather than just the software layer, creating higher deployment barriers but also higher switching costs and stronger network effects from accumulated diagnostic data.

Healx was founded first in 2014, giving it 1 year of additional market experience. SigTuple was founded later in 2015. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Healx has approximately 1-50 employees, while SigTuple has approximately 100-500. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Healx and SigTuple are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.